J. Virchow (Rostock, Germany), I. Satia (Hamilton (ON), Canada)
Blood eosinophil count as a predictor of treatment response in adult patients with chronic cough
A. Rybka (Warsaw, Poland), M. Dabrowska (Warsaw, Poland), E. Grabczak (Warsaw, Poland), K. Bialek-Gosk (Warsaw, Poland), K. Klimowicz (Warsaw, Poland), O. Truba (Warsaw, Poland), R. Krenke (Warsaw, Poland)
|   |
Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough
H. Ishihara (Florham Park, NJ, United States of America), H. Hida (Osaka, Japan), M. Machida (Osaka, Japan), Y. Tsuda (Osaka, Japan), S. Miyazaki (Osaka, Japan)
| |
CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA
A. Papi (Ferrera, Italy), L. Lee (Collegeville, PA, United States of America), H. Kerstjens (Groningen, Netherlands), L. Boulet (Quebec, QC, Canada), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), I. Pavord (Oxford, United Kingdom), G. Brusselle (Ghent, Belgium), N. Barnes (Brentford, Middlesex and London, United Kingdom), N. Hanania (Houston, TX, United States of America), S. Pascoe (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom)
| |
High use of SABAs is associated with higher exacerbation frequency
A. Baron (Groningen, Netherlands), B. Flokstra-De Blok (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), G. Koopmans-Klein ( Leusden, Netherlands), D. Price (Singapore, Singapore), A. Sellink (Den Haag, Netherlands), I. Tsiligianni (Crete, Greece), J. Kocks (Groningen, Netherlands)
| |
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
B. Omarjee (Saint-Denis (La Réunion), Reunion)
| |
Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2
E. Bateman (Cape Town, South Africa), J. Fitzgerald (Vancouver, Canada), H. Reddel (Sydney, Australia), P. Barnes (London, United Kingdom), J. Zheng (Guangzhou, China), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), S. Ivanov (Gothenburg, Sweden), H. Parikh (Gaithersburg, United States of America), V. Alagappan (Gaithersburg, United States of America), P. O'Byrne (Hamilton, Canada)
| |
Characterising asthma exacerbations in the CAPTAIN trial
L. Lee (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Kerwin (Medford, OR, United States of America), H. Kerstjens (Groningen, Netherlands), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), G. Peachey (Stockley Park West, Uxbridge, Middlesex, United Kingdom), N. Sule (Collegeville, PA, United States of America), N. Barnes (Brentford, Middlesex and London, United Kingdom), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), L. Boulet (Quebec, QC, Canada), N. Hanania (Houston, TX, United States of America), R. Nathan (Colorado Springs, CO, United States of America), S. Pascoe (Collegeville, PA, United States of America), I. Pavord (Oxford, United Kingdom), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom)
| |
Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study
W. Meeraus (Stockley Park West, Uxbridge, Middlesex, United Kingdom), S. Zhang (Collegeville, PA, United States of America), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom), L. Lee (Collegeville, PA, United States of America), G. Mu (Collegeville, PA, United States of America), A. Czira (London, United Kingdom), L. Sansbury (Collegeville, PA, United States of America)
| |
Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis
R. Palmér (Gothenburg, Sweden), J. Almquist (Gothenburg, Sweden), M. Hashemi (Gothenburg, Sweden), Z. Taib (Gothenburg, Sweden), S. Necander (Gothenburg, Sweden), K. Korsback (Gothenburg, Sweden), M. Aurell (Gothenburg, Sweden), S. Asimus (Gothenburg, Sweden), S. Delaney (Gothenburg, Sweden), K. Pardali (Gothenburg, Sweden), P. Gustafson (Gothenburg, Sweden), T. Sethi (Gothenburg, Sweden), D. Keeling (Gothenburg, Sweden), I. Psallidas (Gothenburg, Sweden)
| |
PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain)
| |
Oral corticosteroids for asthma usually prescribed by non-specialists
A. van der Meer (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), M. Ferns (Den Haag, Netherlands), M. Krol (Amsterdam, Netherlands), C. Widrich (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)
| |
Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study
K. R. Chapman (Toronto, Canada), K. Kostikas (Ioannina, Greece), H. A.M. Kerstjens (Groningen, Netherlands), P. D'Andrea (New Jersey, United States of America), M. Hosoe (Basel, Switzerland), D. Jain (Basel, Switzerland), A. Pethe (New Jersey, United States of America), A. Tanase (Basel, Switzerland)
| |
Managing T2-High Inflammation in Severe Asthma - Are Biomarkers Better Than Clinician Judgement?
J. Ramsahai (Calgary, Canada), J. Simpson (Newcastle, Australia), A. Cook (Newcastle, Australia), P. Gibson (Newcastle, Australia), V. Mcdonald (Newcastle, Australia), C. Grainge (Newcastle, Australia), P. Wark (Newcastle, Australia)
| |
Effect of indacaterol/mometasone on lung function in adolescents versus overall patient population: PALLADIUM study
M. Krüll (Berlin, Germany), R. Van Zyl-Smit (Cape town, South Africa), C. Gessner (Leipzig, Germany), Y. Gon (Tokyo, Japan), O. Noga (Berlin, Germany), A. Richard (Basel, Switzerland), A. De Los Reyes (New Jersey, United States of America), X. Shu (New Jersey, United States of America), A. Pethe (New Jersey, United States of America), A. Tanase (Basel, Switzerland), P. D'Andrea (New Jersey, United States of America)
| |